Last reviewed · How we verify
Extended course macrolide
Extended course macrolide antibiotics reduce airway inflammation and modulate immune responses in chronic respiratory conditions through anti-inflammatory and immunomodulatory effects.
Extended course macrolide antibiotics reduce airway inflammation and modulate immune responses in chronic respiratory conditions through anti-inflammatory and immunomodulatory effects. Used for Chronic airway inflammatory diseases (likely cystic fibrosis, bronchiectasis, or diffuse panbronchiolitis), Chronic obstructive pulmonary disease with inflammatory phenotype.
At a glance
| Generic name | Extended course macrolide |
|---|---|
| Sponsor | UMC Utrecht |
| Drug class | Macrolide antibiotic (anti-inflammatory/immunomodulatory use) |
| Modality | Small molecule |
| Therapeutic area | Respiratory/Pulmonology |
| Phase | Phase 3 |
Mechanism of action
Macrolides, particularly azithromycin, possess anti-inflammatory properties beyond their antimicrobial action, including inhibition of mucus hypersecretion, reduction of pro-inflammatory cytokine production, and modulation of neutrophil and macrophage function. When administered as extended courses at sub-antimicrobial doses, these agents can suppress chronic airway inflammation and improve clinical outcomes in conditions characterized by persistent inflammation.
Approved indications
- Chronic airway inflammatory diseases (likely cystic fibrosis, bronchiectasis, or diffuse panbronchiolitis)
- Chronic obstructive pulmonary disease with inflammatory phenotype
Common side effects
- Gastrointestinal disturbance (nausea, diarrhea, abdominal discomfort)
- Hearing loss or ototoxicity
- QT prolongation
- Headache
- Taste disturbance
Key clinical trials
- Azithromycin Reduction to Reach Elimination of Trachoma (PHASE4)
- Azithromycin Reduction to Reach Elimination of Trachoma B (PHASE4)
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (PHASE3)
- Comparative Study of 5 Days of M02-472 Clarithromycin Extended-Release Tablets to 7 Days of Clarithromycin Immediate-Release Tablets for the Treatment of Exacerbation of Chronic Bronchitis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Extended course macrolide CI brief — competitive landscape report
- Extended course macrolide updates RSS · CI watch RSS
- UMC Utrecht portfolio CI